Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/44562
Title: Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Authors: Gomes, MB
Rathmann, W
Charbonnel, B
Khunti, K
Kosiborod, M
Nicolucci, A
Pocock, SJ
Shestakova, MV
Shimomura, I
Tang, F
Watada, H
Chen, H
Cid-Ruzafa, J
Fenici, P
Hammar, N
Surmont, F
Ji, L
DISCOVER investigators
First Published: 20-Mar-2019
Publisher: Elsevier for International Diabetes Federation
Citation: Diabetes Research and Clinical Practice, 2019, 151, pp. 20-32
Abstract: AIMS: To describe the characteristics and treatment of patients with type 2 diabetes mellitus initiating a second-line glucose-lowering therapy in the global DISCOVER study programme. METHODS: DISCOVER comprises two similar 3-year prospective observational studies (NCT02322762 and NCT02226822), involving 15,992 patients initiating a second-line glucose-lowering therapy in 38 countries across six regions (Africa, Americas, South-East Asia, Eastern Mediterranean, Europe and Western Pacific). RESULTS: Overall, 54.2% of patients were male (across region range [ARR]: 37.7-58.6%). At baseline, mean age and time since diagnosis of type 2 diabetes mellitus were 57.2 (ARR: 53.1-61.9)and 5.6 (ARR: 4.6-6.9) years, respectively. Median glycated haemoglobin (HbA1c) was 63.9 mmol/mol (8.0%; ARR: 7.6-8.3%). Microvascular and macrovascular complications were reported in 18.9% (ARR: 14.5-23.5%) and 12.7% (ARR: 5.0-26.6%) of patients, respectively. First-line treatments were mostly metformin monotherapy (55.6%; ARR: 42.5-83.6%) and combinations of metformin with a sulfonylurea (14.4%; ARR: 5.8-31.1%). The most commonly prescribed second-line therapies were combinations of metformin with a dipeptidyl peptidase-4 inhibitor (23.5%; ARR: 2.2-29.6%) or a sulfonylurea (20.9%; ARR: 13.6-57.1%). CONCLUSIONS: DISCOVER demonstrates considerable global variation in the treatment of type 2 diabetes mellitus, and a need for more aggressive risk factor control.
DOI Link: 10.1016/j.diabres.2019.03.024
eISSN: 1872-8227
Links: https://www.sciencedirect.com/science/article/pii/S0168822718317455?via%3Dihub
http://hdl.handle.net/2381/44562
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © the authors, 2019. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Description: Supplementary data to this article can be found online at https://doi.org/10.1016/j.diabres.2019.03.024.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
Treatment of type 2 diabetes mellitus worldwide Baseline patient characteristics in the global DISCOVER study.pdfPublished (publisher PDF)500.53 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.